How does NPCU.F's PB Ratio compare to its peers?

Insufficient data to calculate NPCU.F's Price-To-Book Ratio vs. peers for valuation analysis.

How does NPCU.F's PB Ratio compare vs other companies in the US Biotechs Industry?

Insufficient data to calculate NPCU.F's Price-To-Book Ratio vs. industry for valuation analysis.

What is NPCU.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate NPCU.F's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of NPCU.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate NPCU.F's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Allon Therapeutics (OTCPK:NPCU.F) - Stock Price, News & Analysis

NPCU.F Stock Overview

A clinical-stage biotechnology company, focuses on developing and marketing central nervous system therapies. More details

NPCU.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Shares are highly illiquid

Does not have a meaningful market cap ($14K)

Allon Therapeutics Inc. Competitors

ObsEva

OTCPK:OBSE.F

US$117.0

Vaxxinity

OTCPK:VAXX

US$12.7k

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

Histogen

OTCPK:HSTO.Q

US$85.4k

Price History & Performance

Summary of all time highs, changes and price drops for Allon Therapeutics
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-93.33%
5 Year Change	9,900.00%
Change since IPO	-99.95%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	NPCU.F	US Biotechs	US Market
7D	0%	2.4%	0.5%
1Y	n/a	15.6%	30.7%

Return vs Industry: Insufficient data to determine how NPCU.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how NPCU.F performed against the US Market.

Price Volatility

Is NPCU.F's price volatile compared to industry and market?
NPCU.F volatility
NPCU.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: NPCU.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NPCU.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	n/a	n/a	www.allontherapeutics.com

Allon Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing and marketing central nervous system therapies. Its preclinical drug candidate comprises AL-309 for the treatment of peripheral neuropathy. The company was formerly known as Neuro Discovery Inc. and changed its name to Allon Therapeutics Inc. in September 2004.

Allon Therapeutics Inc. Fundamentals Summary

How do Allon Therapeutics's earnings and revenue compare to its market cap?
NPCU.F fundamental statistics
Market cap	US$14.11k
Earnings (TTM)	-US$9.64m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is NPCU.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NPCU.F income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$13.21m
Earnings	-CA$13.21m

Last Reported Earnings

Mar 31, 2013

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did NPCU.F perform over the long term?

See historical performance and comparison